Coeptis Therapeutics Holdings, Inc. - Common Stock (COEP)
11.48
+0.58 (5.32%)
Coeptis Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer patients
The company leverages advanced technologies and scientific expertise to create personalized treatment solutions that aim to improve patient outcomes. Coeptis is dedicated to transforming the landscape of cancer care through its commitment to research and development, actively collaborating with academic institutions and other industry leaders to bring promising therapies from the lab to the clinic. By prioritizing patient-centric approaches, Coeptis seeks to address unmet medical needs in oncology and advance the standard of care for those affected by cancer.
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.
Coeptis Therapeutics Holding Inc. (NASDAQCOEP ) stands tall as a vanguard in the allogeneic cell therapy arena, spearheading groundbreaking solutions for patients battling cancer and other formidable conditions. Let's embark on a journey to explore their remarkable story.
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
Coeptis Therapeutics Holdings, Inc (NASDAQCOEP) ., headquartered in Wexford, Pennsylvania, has established itself as a visionary leader in the biopharmaceutical sector, driving transformative advancements in cell therapy platforms targeting cancer, autoimmune, and infectious diseases. The company has further enhanced its position by embracing artificial intelligence (AI), integrating cutting-edge AI-driven marketing solutions into its strategic framework. This combination of biopharmaceutical innovation and AI-powered tools positions Coeptis to disrupt conventional paradigms and deliver improved patient outcomes while driving operational excellence.
Coeptis Therapeutics Holding Inc. (NASDAQCOEP ) is a biopharmaceutical company making waves in the world of cell therapy, particularly focusing on allogeneic approaches for cancer and other serious diseases. Led by Dave Mehalick (Chairman, President, and CEO) and Brian Cogley (CFO), Coeptis is recognized as a leader in this innovative field.
